Previous 10 | Next 10 |
2024-03-24 08:01:00 ET Westport Fuel Systems ( WPRT ) is set to report its Q4 earnings on Monday after the closing bell. The stock, which has dropped about 24% over a 12-month period, has received a Buy rating from Wall Street analysts, while Seeking Alpha's Quant Rating system has ...
Genesco Inc. (GCO) is expected to report $2.66 for Q4 2024 Broadway Financial Corporation (BYFC) is expected to report for quarter end 2023-12-31 Oji Holdings Corporation ADR (OJIPY) is expected to report for Q3 2024 Hibbett Inc. (HIBB) is expected to report $2.54 for Q4 2024 GRI ...
2024-03-07 11:30:21 ET Summary Galapagos has managed to curtail its R&D and G&A expenses, demonstrating efficient cost management. The company has strategically focused on oncology and immunology, sectors with high unmet medical needs and market impact potential. Galap...
Eurofins Scientific S.E. (ERFSF) is expected to report for Q4 2023 Biodesix Inc. (BDSX) is expected to report $-0.1 for Q4 2023 Tapinator Inc (TAPM) is expected to report for quarter end 2023-12-31 Rapid Micro Biosystems Inc. (RPID) is expected to report $-0.31 for Q4 2023 Galapag...
2024-02-23 10:23:03 ET Galapagos NV (GLPG) Q4 2023 Earnings Conference Call February 23, 2024 8:00 AM ET Company Participants Sofie Van Gijsel - Investor Relations Paul Stoffels - Chief Executive Officer Thad Huston - Chief Financial Officer and Chief Operating O...
Oversea-Chinese Banking Corporation Limited ADR (OVCHY) is expected to report for Q4 2023 Real Brands Inc (RLBD) is expected to report for Q4 2023 NovelStem International Corp (NSTM) is expected to report for Q4 2023 Docebo Inc. (DCBO) is expected to report $0.12 for Q4 2023 Basf ...
Full year 2023 key financials : Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023 Operational cash burn i of €...
- First participant dosed in Phase 1/2 PROSPER trial of FMC-376 in KRAS G12C Cancers - FMC-376 is a first-in-class direct dual inhibitor of ON+OFF KRAS G12C - FMC-376 has the potential to transform patient outcomes wi...
2024-02-21 17:20:53 ET More on Galapagos Galapagos enters into strategic collaboration with Thermo Fisher Galapagos signs development deal with BridGene Seeking Alpha’s Quant Rating on Galapagos Historical earnings data for Galapagos Financial ...
Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 CAR-T studies Mechelen, Belgium; 15 February 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) to present new preliminary translatio...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...